DNA topoisomerase I (Top1) is the target of camptothecin and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3'-end of the broken DNA.
Introduction
DNA topoisomerase I (Top1) is ubiquitous and essential in higher eukaryotes. It relieves DNA torsional stress and relaxes DNA supercoiling by introducing DNA single-strand breaks, which are produced by the covalent linking of the Top1 catalytic tyrosine residue (Y723 in humans) to a 3'-DNA phosphate. Thus, these breaks are referred to as "Top1 cleavage complexes" (Champoux, 2001; Wang, 2002) . Once the DNA is relaxed, each break is religated as the 5'-end of the broken DNA reseals the break by attacking the phosphotyrosyl bond, which releases Top1. Top1-DNA cleavage complexes are normally undetectable because they are very transient [for review see (Champoux, 2001; Pommier et al., 1998; Wang, 2002) .
Top1 cleavage complexes can selectively be trapped by the natural alkaloid camptothecin (Hsiang et al., 1985) as the drug binds at the enzyme-DNA interface and prevents DNA religation (Pommier and Cherfils, 2005) . Two camptothecin derivatives are used in cancer therapy: hycamtin (Topotecan ® ) and Camptosar ® ) and several families of non-camptothecin inhibitors are being developed as novel anticancer agents . Top1 cleavage complexes can also be trapped by endogenous DNA lesions including abasic sites, mismatches, oxidized bases, nicks and carcinogenic DNA adducts (Pommier et al., 2006; Pommier et al., 2003; Pourquier and Pommier, 2001) . Hence, DNA modifications such as those associated with oxidative damage [thousands per cell per day] can stabilize Top1 cleavage complexes (Pourquier and Pommier, 2001; Sordet et al., 2004) . By contrast to camptothecins and other Top1 inhibitory drugs, these DNA modifications produce irreversible cleavage complexes when the 5'-end of the DNA is irreversibly misaligned as in the case of abasic sites or DNA breaks (Pommier et al., 2006; Pommier et al., 2003; Pourquier and Pommier, 2001 ). The irreversible cleavage complexes are commonly referred to as "suicide complexes". Reversible cleavage complexes trapped by drugs can also be converted into irreversible complexes after collision of replication forks or transcription complexes with the Top1 cleavage complexes [reviewed in ].
Tyrosyl-DNA phosphodiesterase (Tdp1) was discovered as an enzyme that specifically removes the 3'-phosphotyrosyl adducts (Pouliot et al., 1999; Yang et al., 1996) . Top1 needs to be proteolyzed (Debethune et al., 2002) or denatured (Interthal et al., 2005a) for This article has not been copyedited and formatted. The final version may differ from this version. Tdp1 to hydrolyze the tyrosyl-DNA bond. Top1 degradation and ubiquitination have indeed been observed following camptothecin treatment (Desai et al., 1997) . Tdp1 orthologs are present in all eukaryotic species examined, including yeasts and humans (Interthal et al., 2001; Pouliot et al., 1999) . Sequence comparisons (Interthal et al., 2001) and structural studies (Davies et al., 2002b) revealed that Tdp1 is a member of the phospholipase D (PLD) superfamily, which also includes a bacterial toxin, poxvirus envelope proteins, and bacterial nucleases (Interthal et al., 2001 ).
In humans, homozygous mutation in the TDP1 gene (1478A-G) resulting in substitution of histine 493 with arginine is responsible for "spinocerebellar ataxia with axonal neuropathy" (SCAN1) (Paulson and Miller, 2005; Takashima et al., 2002) . Recent studies demonstrated that SCAN1 cells are hypersensitive to camptothecin (Interthal et al., 2005b) and that Tdp1 is required for the repair of abortive Top1 cleavage complexes (El-Khamisy et al., 2005) . Tdp1 forms multi-protein complexes with the single-strand break repair XRCC1 complexes (Plo et al., 2003) by direct interaction with DNA ligase III (El-Khamisy et al., 2005) . These complexes are catalytically defective in SCAN1 cell extracts (El-Khamisy et al., 2005) , which accumulate Tdp1-DNA intermediates (Interthal et al., 2005b) . Tdp1 can also remove glycolate residues from the 3'-end of DNA (Inamdar et al., 2002) . 3'-phosphoglycolate is a common byproduct of DNA doublestrand breaks caused by oxidative fragmentation of DNA sugars, which occur as a result of ionizing radiation and oxidative DNA damage (Inamdar et al., 2002) . Consistently, extracts from SCAN1 cells are deficient in processing 3'-phosphoglycolate (Zhou et al., 2005) . Thus, Tdp1 appears to repair Top1-DNA adducts and free-radical-mediated DNA breaks. Since the later can also generate Top1 covalent complexes (Pourquier and Pommier, 2001) , Top1repair is probably a critical function of Tdp1.
In budding yeast, a T722A mutant Top1 that induces high level of cleavage complexes by increasing their stability results in low viability ). However, Tdp1 deficiency alone does not confer hypersensitivity to Top1 cleavage complexes unless an additional mutation of the RAD9 checkpoint gene or the RAD1 endonuclease gene (Liu et al., 2002; Vance and Wilson, 2002 ) is associated with a Tdp1 null-mutation [reviewed in (Pommier et al., 2006; Pommier et al., 2003) (Barthelmes et al., 2004) . Because cancer cells are characteristically defective in checkpoint and DNA repair, and oncogenic transformation produces high levels of oxidative radicals, it is plausible that Tdp1 inhibitors might be used for anticancer treatment alone or more likely in combination with camptothecins or other Top1
inhibitors.
The present study reports the first pharmacological inhibitors for Tdp1. The only other inhibitors of Tdp1 are vanadate and tungstate, which are general inhibitors of a variety of enzymes involved in phosphoryl transfer reactions (Davies et al., 2002a) . Using recombinant human Tdp1 and model tyrosyl-oligonucleotides substrates, we show that antibiotics that target bacterial ribosomes can inhibit Tdp1 activity. Preparation of human Tdp1. Human Tdp1 expressing plasmid pHN1910 (a gift from Dr.
MATERIALS AND METHODS
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Howard Nash, Laboratory of Molecular Biology, NIMH, NIH) was constructed using vector pET-15b (Novagen, San Diego, CA) with full length human Tdp1 and an additional His-tag sequence of MGSSHHHHHHSSGLVPRGSHMLEDP in its Nterminus. The His-tagged human Tdp1 was purified from Novagen BL21 cells using HiTrap™ Chelating HP (Amersham Biosciences, Piscataway, NJ) according to the company's protocol. Samples were assayed immediately. Tdp1 fractions were pooled and dialyzed with dialysis buffer (10% glycerol, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM β-mercaptoethanol, 2 mM EDTA). Dialyzed samples were aliquoted and stored at -80 o C. Tdp1 concentration was determined using Bradford protein assay (Bio-rad Laboratories, Hercules, CA) and its purity was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (see Fig. 1B ).
This article has not been copyedited and formatted. The final version may differ from this version. Preparation of Tdp1 substrates. HPLC purified oligonucleotides N14Y (see Fig. 1A ) (Plo et al., 2003) 
Results
This article has not been copyedited and formatted. The final version may differ from this version. Inhibition of Tdp1 by aminoglycosides and other antibiotic ribosome inhibitors. It was reported that sodium vanadate, a phosphatase inhibitor inhibits Tdp1 activity (Davies et al., 2002a) . As expected, vanadate inhibited Tdp1 under our assay conditions (Fig. 1C) .
Its inhibitory activity has been related to its phosphate-mimicking activity and/or its activity as a transition state analog (Davies et al., 2002a; Davies et al., 2003; Davies et al., 2004) . Because Tdp1 is a member of phospholipase D superfamily (Davies et al., 2002b) and neomycin was reported to inhibit PLD (Huang et al., 1999) , we tested whether neomycin could also inhibit Tdp1 activity. Using Tdp1 biochemical assays (Fig.   1A ), we found that neomycin also inhibits purified recombinant Tdp1 (Fig. 1C-D) . The two neomycin analogs, paromomycin and lividomycin also inhibited Tdp1 activity at slightly higher concentrations (Fig. 1D ). Because neomycin, paromomycin, lividomycin and other aminoglycosides are known inhibitors of bacterial ribosomes (Schroeder et al., 2000) , we tested other aminoglycosides and non-aminoglycoside ribosomal inhibitors (Moore and Steitz, 2003) . Figure 2A shows the structures and Tdp1 inhibitors activity of various ribosomal inhibitors against Tdp1. The most active inhibitors were neomycin (IC 50 = 8 mM) and thiostrepton (1.8 mM). However, some activity was found for clindamycin-2-phosphate and puromycin albeit at higher concentration. Although these concentrations are high, reactions were performed at saturating Tdp1 activity (20 min reactions with 1 ng Tdp1; see Fig. 4A and Fig. 5 for greater inhibition under different conditions).
Neomycin inhibits the processing of both duplex and single-stranded DNA by Tdp1.
As partially duplex DNA and single-stranded DNA are both substrates for Tdp1 (Davies et al., 2003; Pouliot et al., 2001; Yang et al., 1996) , we compared the inhibition of Tdp1 by neomycin using the D14Y and N14Y substrates (Fig. 3) . Panels A and B (Fig. 3) show that neomycin inhibits the processing of both the single-and double-stranded substrates by Tdp1 although neomycin was slightly more effective with the duplex substrate. By contrast, sodium vanadate was similarly active with both single-and double-stranded substrates, and aclarubicin, a known DNA intercalator inhibited Tdp1 selectively with This article has not been copyedited and formatted. The final version may differ from this version. double-stranded DNA (Fig. 3C) . We conclude that neomycin inhibits Tdp1 activity both with single-and double-stranded DNA substrates. and circles in panels B and C) shows that under these conditions, Tdp1 converted more than 90% of the D14Y substrate within 3 minutes. Thus, we wished to determine whether concentrations of neomycin below its determined IC 50 would affect the kinetics of Tdp1 activity. Tdp1 activity was slowed down at 1 mM neomycin, a concentration producing no detectable inhibition after a 20 min reaction ( Fig. 4A and B) . Kinetic plots demonstrated that 1 mM neomycin increased the conversion half-time (T1/2) of D14Y from 0.5 min in the absence of drug to 3 min in the presence of 1 mM neomycin and 8 min in the presence of 2 mM neomycin (Fig. 4C) . These experiments suggest that neomycin produces reversible inhibition of Tdp1. Increasing Tdp1 concentration was able to overcome Tdp1 inhibition by neomycin even when neomycin was present at 10 mM drug concentration ( Fig. 5A-B) . Thus, free
Kinetics of
Tdp1 competes with neomycin. Moreover, if DNA were the only target of neomycin, inhibition should not depend on Tdp1 concentration, which is not what we observed ( Fig.   5A-B) . These results suggest that neomycin inhibiting Tdp1 by binding directly to Tdp1.
This article has not been copyedited and formatted. The final version may differ from this version. Neomycin tends to be protonated and to bind nucleic acids better at acidic pH than at pH 8.0, which is the pH used in the prior experiments and in previous publications (Debethune et al., 2002; Pouliot et al., 2001; Pouliot et al., 1999; Raymond et al., 2004) .
As nuclear pH is also acidic, we examined Tdp1 inhibition by neomycin at pH 6.4. Figure   5C shows that Tdp1 activity decreases with pH (Raymond et al., 2005) . Nevertheless, after 20 min reaction (dotted line in Fig. 5C ), substrate processing was nearly the same at pH 6.4 and 8. Under these conditions, neomycin was more effective at pH 6.4 than at pH 8.0 (IC 50 = 1.8 mM vs. 8 mM, respectively) (Fig. 5D ).
To gain an appreciation of neomycin IC 50 at physiological pH under non-saturating conditions, we lowered Tdp1 concentration to 0.1 ng and the Tdp1 reaction time to 8 min. Figure 5D shows that under these conditions, the IC 50 for neomycin was approximately 0.25 mM, which is in the range of concentrations for inhibition of the ribosome and the spliceosome.
Discussion
This study suggests that antibiotics could serve as a basis for the discovery and design of Tdp1 inhibitors. Tdp1 is conserved from yeast to humans, which suggests its functional importance. Tdp1 is involved in the removal of covalent Top1-DNA complexes following degradation or denaturation of the Top1 polypeptide covalently linked to the 3'-end of DNA (Debethune et al., 2002; Interthal et al., 2005a; Yang et al., 1996) . Tdp1 is also involved in the repair of oxidative damage by removing glycolate residues from the 3'-end of DNA breaks (Inamdar et al., 2002; Zhou et al., 2005) . The development of Tdp1 inhibitors as anticancer agents can be envisioned as combinations of Tdp1 and Top1 inhibitors. Tumor cells, whose repair pathways are commonly deficient, might be selectively sensitized to Top1 inhibitors compared to normal cells that contain redundant repair pathways. Moreover, Tdp1 inhibitors might also be effective by themselves as anticancer agents as oncogenic activation tends to increase free radical production and genomic instability (Cerutti, 1985) . Also, Tdp1 inhibitors might be valuable as antiinfectious agents since the gene is present in parasites.
This article has not been copyedited and formatted. The final version may differ from this version. The inhibitors reported in the present study all bind RNA motifs present in bacterial ribosomes. Neomycin is a polycationic aminoglycoside antibiotic with a four-membered ring structure consisting of a 2-deoxystreptamine ring linked to several amino sugars (Kotra et al., 2000 ) (see Fig. 2A ). Neomycin interacts with the 16S rRNA of the 30S ribosomal subunits within an internal loop in the decoding site (Schroeder et al., 2000) .
Binding between the rRNA of the internal loop and rings I and II of the aminoglycoside antibiotic distort the A-site and leads to amino acid misincorporation (Moore and Steitz, 2003; Ogle et al., 2001; Schroeder et al., 2000) . Neomycin, which differs in structure from paromomycin by the change of single amino group by hydroxyl on the C'6 position of ring I ( Fig. 2A) , showed approximately 2-fold greater inhibition for Tdp1 than paromomycin and lividomycin ( Fig. 2A) . Protonation of the neomycin amino groups is probably important for inhibition since neomycin was more effective at pH 6.4 than pH 8.0 (approximately 4-fold) (Fig. 5D) . The same increase in activity at acidic pH (pH 6.4
is close to cellular nuclear pH) was also observed for paromomycin and lividomycin (data not shown), which indicates that protonation increases the inhibitory activity of aminoglycosides.
Although protonation increases the binding of neomycin to RNA, our experiments suggest that the inhibitory effect of neomycin is probably not simply related to nucleic acid binding. We found no Tdp1 inhibition for the polyamines spermine and spermidine (our unpublished data). If neomycin was primarily targeting the DNA substrate, one would have expected that pre-incubation of neomycin with DNA would enhance inhibition. However, preincubation experiments (Fig. 4C) showed that neomycin was less efficient against Tdp1 when it was first incubated with DNA. In our experiments, the tyrosyl-DNA substrate is at much lower concentration than neomycin. The concentration ratio is: 25/10 6 (i.e. the drug is in 40,000-fold excess compared to the DNA). Therefore, it is unlikely that binding of neomycin to the DNA substrate would reduce the concentration of free drug. Moreover, if DNA were the main target of neomycin, increasing Tdp1 concentration would not have been expected to affect Tdp1 inhibition by neomycin, which is not the case since inhibition is in fact inversely related to the Tdp1 concentration ( Fig. 5A-B) . Also, neomycin inhibits Tdp1 activity toward both single-and double-stranded DNA substrates (Fig. 3) , whereas neomycin is known to bind duplex This article has not been copyedited and formatted. The final version may differ from this version. RNA (Moore and Steitz, 2003; Schroeder et al., 2000) . Therefore, we propose that neomycin binds either directly to Tdp1 or to the Tdp1-DNA complex interface. The latter possibility would characterize neomycin as a potential interfacial inhibitor. However, if neomycin stabilizes the Tdp1-DNA intermediate, we were not able to detect the resulting complex at the top of the gels under the electrophoresis conditions (Interthal et al., 2005b) . Interfacial inhibition has recently emerged as a common mechanism for natural drugs against a variety of targets including protein-DNA interfaces in the case of camptothecin and antibiotics (Pommier and Marchand, 2005) , and protein-protein interfaces in the case brefeldin A, colchicine, paclitaxel or vinblastine as tubulin inhibitors (Pommier and Cherfils, 2005) .
Further studies are warranted to determine the Tdp1 binding site of aminoglycoside antibiotics, clindamycin-2-phosphate, puromycin and thiostrepton (see Fig. 2 ). Neomycin is also known to inhibit (bind to) phospholipase D, which does not contain RNA or DNA (Huang et al., 1999) . Neomycin acts as an uncompetitive inhibitor of PLD by binding to the PLD activator PIP2 or, alternatively, to the PIP2-PLD complex to form a ternary complex (Huang et al., 1999) .
Several crystal structures of human Tdp1 have been determined in the absence or presence of peptide-nucleic acid ligands (Davies et al., 2002a; Davies et al., 2002b; Davies et al., 2003; Davies et al., 2004; Interthal et al., 2001) . Although Tdp1 contains a positively charged groove that accommodates the nucleic acid substrate, it also contains clusters of negatively charged residues in the vicinity of the active site (Davies et al., 2003) . These acidic residues might bind the neomycin polycations. Co-crystallization of the antibiotics described is warranted to elucidate the drug binding site and the potential contribution of the peptide-nucleic acid substrate for drug binding to Tdp1. Such studies may also guide the discovery and design of more potent and more selective Tdp1
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